Keyphrases
5-fluorocytosine
100%
5-fluorouracil (5-FU)
45%
96-well Plate
9%
Adenoviridae Infections
9%
Athymic nude Mice
9%
Cancer Therapy
9%
Cell Killing
27%
Cell Proliferation Assay
9%
Cell Toxicity
9%
Chemotherapy
9%
Chemotherapy Strategies
9%
Cholangiocarcinoma
27%
Cholangiocarcinoma Cells
100%
Clonogenic Assay
18%
Colorimetric Assay
9%
Combined Treatment
9%
Curvature Parameter
9%
Cytomegalovirus Promoter
9%
Cytosine Deaminase
9%
Cytotoxic Effect
9%
Cytotoxicity
18%
Doubling Time
9%
Escherichia Coli
18%
Exposure Time
9%
External Beam Radiation
27%
FACS Analysis
9%
Fluorescence-activated Cell Sorting
9%
Formazan
9%
Gene Conversion
9%
Gene Therapy
9%
Great Changes
9%
HeLa Cells
9%
High Efficiency
9%
Human Cholangiocarcinoma
9%
Human Cholangiocarcinoma Cell Lines
9%
Human Cytomegalovirus
9%
In Cancer
9%
Infected Cells
9%
Infection Therapy
9%
Intratumoral Injection
9%
Molecular Chemotherapy
100%
MTS Assay
9%
Non-radiation
9%
Plaque-forming Units
36%
Prior Exposure
9%
Prodrug
18%
Prodrug Therapy
9%
Radiation Dose Response
18%
Radiation Exposure
9%
Radiation Therapy
100%
Radiobiological Parameters
9%
Radiosensitization
9%
Radiotherapy
9%
Recombinant
9%
Recombinant Adenovirus
18%
Recombinant Viral Vectors
9%
Reporter Gene
9%
Response Time Analysis
18%
Salt Conversion
9%
Sorting Analysis
9%
Survival Curve
9%
Survival Time
9%
Tetrazolium Salts
9%
Therapy Strategy
9%
Time to Tumor
9%
Toxin Genes
9%
Treatment Conditions
9%
Treatment Group
36%
Tumor
36%
Tumor Inhibition
9%
Tumor Regrowth
9%
Tumor Size
36%
Twice Daily
9%
β-Galactosidase (β-Gal)
9%
Medicine and Dentistry
Adenoviridae
18%
Adenovirus Infection
9%
Adenovirus Vector
9%
Antiinfective Agent
18%
Arsphenamine
9%
Cancer Inhibition
9%
Cancer Therapy
9%
Cell Killing
27%
Cell Proliferation Assay
9%
Cholangiocarcinoma
100%
Cholangiocarcinoma Cell Line
9%
Clonogenic Assay
18%
Cobalt 60
18%
Colorimetry
9%
Cytosine Deaminase
9%
Cytotoxicity
36%
Dose Response
18%
Escherichia coli
18%
External Beam Radiotherapy
27%
Flucytosine
100%
Fluorescence Activated Cell Sorting
18%
Fluorouracil
36%
Formazan
9%
Galactosidase
9%
Gene Conversion
9%
Gene Therapy
9%
Human Cytomegalovirus
9%
In Vitro
100%
Infection
27%
Intratumoral Drug Administration
9%
Minoxidil
9%
MTS Assay
9%
Neoplasm
81%
Prodrug
27%
Promoter Region
9%
Radiation Exposure
9%
Radiation Therapy
100%
Reporter Gene
9%
Survival Rate
9%
Survival Time
9%
Tetrazolium
9%
Treatment Group
36%
Immunology and Microbiology
Adenoviridae
50%
Adenovirus Vector
25%
Cell Killing
75%
Cell Proliferation
25%
Cholangiocarcinoma Cell Line
25%
Clonogenic Assay
50%
Cytotoxicity
100%
Dose Response
50%
Escherichia coli
50%
Fluorescence Activated Cell Sorting
50%
Galactosidase
25%
Gene Conversion
25%
Growth Inhibition
25%
Human Cytomegalovirus
25%
Nude Mouse
25%
Plaque-Forming Unit
100%
Promoter Region
25%
Radiation Beam
75%
Reporter Gene
25%
Survival Rate
25%
Survival Time
25%
Tumor Volume
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adenoviridae
18%
Adenovirus Infection
9%
Adenovirus Vector
9%
Antiinfective Agent
18%
Arsphenamine
9%
Bile Duct Carcinoma
100%
Cancer Inhibition
9%
Chemotherapy
100%
Cobalt 60
18%
Cytosine Deaminase
9%
Cytotoxicity
36%
Escherichia coli
18%
Flucytosine
100%
Fluorescence Activated Cell Sorting
18%
Fluorouracil
36%
Formazan
9%
Galactosidase
9%
Human Cytomegalovirus
9%
Infection
27%
Malignant Neoplasm
9%
Minoxidil
9%
Neoplasm
81%
Nude Mouse
9%
Prodrug
27%
Radiation Exposure
9%
Survival Rate
9%
Survival Time
9%
Tetrazolium
9%
Treatment Group
36%